| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
The molecular targets are MAO-B, with safinamide inhibiting the enzyme with an IC50 of 0.098 μM (98 nM) and showing greater than 1000-fold selectivity over MAO-A (IC50 580 μM); it also blocks voltage-gated sodium channels and modulates glutamate release, and these activities may contribute to its anticonvulsant and neuroprotective effects.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
In vitro, safinamide-d4 inhibits human and rat brain MAO-B with IC50 values of 79 nM and 98 nM, respectively, and is approximately 1000- to 6000-fold selective over MAO-A; it blocks sodium channels and reduces veratridine-induced glutamate release, and the deuterated form retains full MAO-B inhibitory activity. |
| ln Vivo |
In vivo, oral safinamide-d4 increases striatal dopamine and phenylethylamine levels and potentiates levodopa-induced motor improvements in Parkinson’s disease models; it also reduces glutamate release and provides anticonvulsant effects in seizure models, and the labeled form is used to quantify plasma and brain exposure.
|
| Enzyme Assay |
Noncellular MAO-B inhibition assays incubate human recombinant MAO-B or rat brain mitochondrial preparations with benzylamine or phenylethylamine and increasing concentrations of safinamide-d4; amine oxidation is measured spectrophotometrically or by HPLC, and IC50 values are derived, with reversibility assessed by preincubation and dilution.
|
| Cell Assay |
Cellular assays use SH-SY5Y neuroblastoma cells, platelets, or MAO-B–transfected HEK293 cells treated with safinamide-d4; MAO-B activity in cell lysates is measured with a fluorogenic substrate, dopamine and phenylethylamine levels by HPLC, and sodium channel blockade by patch-clamp electrophysiology.
|
| Animal Protocol |
Animal protocols administer safinamide-d4 orally or intraperitoneally to rats or mice at doses of 1–30 mg/kg; brain and platelet MAO-B activity is measured ex vivo, striatal dopamine and glutamate levels are quantified by microdialysis or HPLC, and locomotor activity and levodopa-induced dyskinesia models are used to relate MAO-B inhibition and sodium channel blockade to behavioral outcomes.
|
| References |
|
| Molecular Formula |
C17H19FN2O2
|
|---|---|
| Molecular Weight |
302.343367815018
|
| Exact Mass |
306.168
|
| CAS # |
2748522-33-8
|
| Related CAS # |
Safinamide;133865-89-1
|
| PubChem CID |
163322464
|
| Appearance |
White to off-white solid
|
| LogP |
2.2
|
| tPSA |
64.4
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
22
|
| Complexity |
346
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
[2H]C1=C(C(=C(C(=C1CN[C@@H](C)C(=O)N)[2H])[2H])OCC2=CC(=CC=C2)F)[2H]
|
| InChi Key |
NEMGRZFTLSKBAP-CSYJRVKYSA-N
|
| InChi Code |
InChI=1S/C17H19FN2O2/c1-12(17(19)21)20-10-13-5-7-16(8-6-13)22-11-14-3-2-4-15(18)9-14/h2-9,12,20H,10-11H2,1H3,(H2,19,21)/t12-/m0/s1/i5D,6D,7D,8D
|
| Chemical Name |
(2S)-2-[[2,3,5,6-tetradeuterio-4-[(3-fluorophenyl)methoxy]phenyl]methylamino]propanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3075 mL | 16.5377 mL | 33.0753 mL | |
| 5 mM | 0.6615 mL | 3.3075 mL | 6.6151 mL | |
| 10 mM | 0.3308 mL | 1.6538 mL | 3.3075 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.